Organisation paid for research Program year 2025 Source: CMS Open Payments

Parexel

Neither a doctor nor a teaching hospital

Research payments

$5,285,685

37 payments

Through program year 2025, Parexel is reported as receiving $5,285,685 in research payments, across 37 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $13,042 1
2023 Research $427,966 4
2022 Research $60,992 1
2021 Research $2,504,201 21
2020 Research $86,116 3
2019 Research $2,193,368 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Co., Ltd. $2,188,547 1 payment
  2. ViiV Healthcare Company $1,735,676 14 payments
  3. GlaxoSmithKline, LLC. $1,288,717 13 payments
  4. Merck Sharp & Dohme Corporation $59,703 8 payments
  5. AstraZeneca Pharmaceuticals LP $13,042 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase 1 clinical study research for protocol VIS649-101, IND number 135282 $2,188,547 1 payment
  2. A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Si $1,735,676 14 payments
  3. A Phase I, Single-Blind, Randomized, Single-Dose Clinical Pharmacology $785,529 9 payments
  4. A Phase 1 Double-Blind (Sponsor-Unblinded), Placebo-Controlled Randomi $423,220 2 payments
  5. A Three-Part Ftih Study to Evaluate Safety, Tolerability, Pharmacokine $79,428 1 payment
  6. A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult Participants With Schizophrenia and to Evaluate the Safety, Tolerability and Pharmacokinetics of MK 8189 in Elderly Participants With Schizophrenia and Healthy Elderly $54,883 2 payments
  7. A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine $13,042 1 payment
  8. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of V172 in Healthy Younger Participants Ages 18 and 49 Years and Healthy Older Participants Ages 60 and 79 Years $3,638 3 payments
  9. A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer s Clinical Syndrome on a Stable Dose of Donepezil $713 1 payment
  10. A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Para $539 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record